Pharmacology/Pharmaceutical Industry | Page 84 of 172 | Links Medicus Content Curation & Alerts in Medicine

Both the Pfizer BioNTech and the Oxford AstraZeneca vaccines are highly effective in reducing covid-19 infections and protecting against severe disease in older adults, preliminary data show https://t.co/THSv5kiIVt

— The BMJ (@bmj_latest) March 2, 2021

Requests for brand name over generic prescription drugs cost the Medicare program $1.7 billion in a single year, study finds

3 Mar, 2021 | 08:31h | UTC

News release: Requests for brand name over generic prescription drugs cost the Medicare program $1.7 billion in a single year, study finds – Johns Hopkins Bloomberg School of Public Health

Original study: Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program – JAMA Network Open

Commentary on Twitter

Economic evaluation finds prescribers & patients motivated 30% of branded drug dispensing in Medicare Part D, an incremental annual cost of $1.7 billion Medicare & $270 million to patients vs switching to generics. @dr_msocal @GeBaiDC @JohnsHopkinsSPH https://t.co/MkVJdzLczG

— JAMA Network Open (@JAMANetworkOpen) March 3, 2021

RCT: Effect of Blinatumomab vs. Chemotherapy in children with high-risk first-relapse B-Cell Acute Lymphoblastic Leukemia

3 Mar, 2021 | 08:19h | UTC

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia – JAMA (free for a limited period)

RCT: Omega-3 supplements do not reduce cardiovascular events in elderly patients after myocardial infarction

3 Mar, 2021 | 08:13h | UTC

Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial – Circulation (link to abstract – $ for full-text)

Commentary: Omega-3 fatty acids did not reduce risk of cardiac events in elderly heart attack survivors – News Medical

Commentary on Twitter

OMEMI: In RCT of elderly patients with a recent acute myocardial infarction, n-3 fatty acid supplementation did not reduce clinical events. Read more: https://t.co/nGs5DGGtmT #AHAJournals @Oslounivsykehus @UniOslo @pmyhre @AAKalstad pic.twitter.com/I3Gr89ztyj

— Circulation (@CircAHA) February 11, 2021

Serious bradycardia and Remdesivir for COVID-19: a new safety concern

2 Mar, 2021 | 02:06h | UTC

Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns – Clinical Microbiology and Infection

Commentary on Twitter

⛔A new safety concern⛔
New 🔥 post-marketing study @CMIJournal suggests that the use of remdesivir is significantly associated with an increased risk of reporting serious bradycardia compared with HCQ,LPV/RTV, tocilizumab or glucocorticoids #IDTwitter https://t.co/npLMchifEM

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) February 27, 2021

Consensus Document: Venous thromboembolism prophylaxis in the trauma intensive care unit

2 Mar, 2021 | 01:52h | UTC

Venous thromboembolism prophylaxis in the trauma intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document – Trauma Surgery & Acute Care Open

Who gets a COVID-19 vaccine and who pays? The need for economic analysis

2 Mar, 2021 | 02:02h | UTC

Who Gets a COVID-19 Vaccine and Who Pays? The Need for Economic Analysis – Center for Global Development

Commentary on Twitter

NEW from @CGDev and @idsihealth — experts look at the potential of Health Technology Assessment (HTA) on informing how much #COVID19 vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.

Read: https://t.co/KuMZSARSEF #GlobalHealth

— Center for Global Development (@CGDev) February 24, 2021

Systematic review: Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge

2 Mar, 2021 | 01:46h | UTC

Safety and efficacy of de-labelling penicillin allergy in adults using direct oral challenge: a systematic review – JAC-Antimicrobial Resistance

Commentary on Twitter

“Direct oral challenge safe & effective for de-labelling patients at low risk for true allergy. Important for optimizing patient care and tackling #AMR” https://t.co/S3VL8JXyFJ #JACAMRNews #AMR #AMS @SAPGAbx @lac_cooper @jenny_harbour @raseaton66 @jacquisneddons pic.twitter.com/SwE1yyVr8d

— JAC-AMR (@jac_amr) February 23, 2021

CDC Report: Reduction in severe COVID-19 following the implementation of a national vaccination program in Israel

28 Feb, 2021 | 21:54h | UTC

Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021 – CDC Morbidity and Mortality Weekly Report

Commentary: Israeli data suggest mass vaccinations led to drop in severe Covid cases, CDC study finds – CNBC

Commentary on Twitter

A new @CDCMMWR from Israel shows preliminary evidence of the effectiveness of vaccination in preventing severe cases of #COVID19. Vaccination among people who are eligible to receive a COVID-19 vaccine can potentially reduce severe disease from COVID-19. https://t.co/CaUAXRVaS4 pic.twitter.com/GyaulMONpZ

— CDC (@CDCgov) February 26, 2021

Short Review: SARS-CoV-2 Vaccines

28 Feb, 2021 | 21:52h | UTC

SARS-CoV-2 Vaccines – JAMA

Author interview: Coronavirus Vaccines—An Overview

Check out the Table ins this #SARSCoV2 Vaccine Overview – everything you wanted to know about upcoming vaccines – Oxford/AZ, Sputnik, Sinovac, more! https://t.co/TWbgfSKBIP

— JAMA (@JAMA_current) February 26, 2021

Studies: Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection

28 Feb, 2021 | 21:49h | UTC

Single dose of vaccine acts as ‘booster’ in those with prior COVID-19 infection – Imperial College London

Study 1: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals – The Lancet

Study 2: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine – The Lancet

Commentary on Twitter (thread – click for more)

New on 1-dose @Pfizer vaccine after prior covid
"We show that individuals with previous #SARSCoV2 infection generate strong humoral and cellular responses to one dose of BNT162b2 vaccine, with evidence of high titres of in-vitro live virus neutralisation"https://t.co/2G7TRu57OI pic.twitter.com/sIdB0VarqB

— Eric Topol (@EricTopol) February 25, 2021

Spain to give just one vaccine dose to under 55-year olds who had COVID-19

28 Feb, 2021 | 21:47h | UTC

Spain to give just one vaccine dose to under 55-year olds who had COVID-19 – Reuters

New report reviews methods for reducing waste, improving efficiency with expensive injectable medications

28 Feb, 2021 | 21:29h | UTC

New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications – The ASCO Post

Summary: Medications in Single-Dose Vials and Implications of Discarded Injectable Drugs: A National Academies Report – JAMA

Original report: Medications in Single Dose Vials: Implications of Discarded Drugs (2021) – National Academies of Sciences, Engineering, and Medicine

Commentary on Twitter

"significant amounts of expensive injectable or infused drugs, distributed in single-dose vials, are discarded" but hard to quantify.

Medications in Single-Dose Vials and Implications of Discarded Injectable Drugs: A National Academies Report https://t.co/z3ebKGIcEg

— Suresh Nirody – snirody.eth (@snirody) February 26, 2021

RCT: Baclofen reduces agitation in patients with unhealthy alcohol use receiving mechanical ventilation, but results in a longer time receiving mechanical ventilation and more extended ICU stay

28 Feb, 2021 | 21:09h | UTC

Effect of High-Dose Baclofen on Agitation-Related Events Among Patients With Unhealthy Alcohol Use Receiving Mechanical Ventilation: A Randomized Clinical Trial – JAMA

Editorial: Baclofen to Prevent Agitation Caused by Alcohol Withdrawal in the ICU

Video presentation: Effect of Baclofen on Agitation-Related Events Among Mechanically Ventilated Patients With Alcohol Use Disorder

Commentary on Twitter

In this phase 3 RCT, high-dose baclofen reduced agitation-related events vs placebo in patients with unhealthy alcohol use receiving mechanical ventilation; considering the modest effect & secondary endpoints & adverse events, further research is needed https://t.co/gHWEqZKfFv

— JAMA (@JAMA_current) February 23, 2021

RCT: Balanced opioid-free anesthesia with Dexmedetomidine resulted in a greater incidence of serious adverse events, especially hypoxemia and bradycardia

28 Feb, 2021 | 21:03h | UTC

Balanced Opioid-free Anesthesia with Dexmedetomidine versus Balanced Anesthesia with Remifentanil for Major or Intermediate Noncardiac Surgery: The Postoperative and Opioid-free Anesthesia (POFA) Randomized Clinical Trial – Anesthesiology

Bioethics | Should clinical guidelines incorporate cost pathways for persons with financial hardship?

28 Feb, 2021 | 20:54h | UTC

Should Clinical Guidelines Incorporate Cost Pathways for Persons With Financial Hardship? – AMA Journal of Ethics

Joint Statement: Hydroxychloroquine use with respect to retinal toxicity

28 Feb, 2021 | 20:41h | UTC

ACR, AAD, RDS, and AAO 2020 Joint Statement on Hydroxychloroquine Use with Respect to Retinal Toxicity – Arthritis & Rheumatism

Commentary: Societies Agree on Eye Safety for HCQ – MedPage Today (free registration required) AND ACR, medical societies reach consensus on hydroxychloroquine retinopathy – Healio (free registration required)

Commentary on Twitter

🆕 Joint statement on #Hydroxychloroquine use with respect to retinal toxicity 👀 by several #rheumatology and #opthtalmology societies. #ocular #toxicity relates to #HCQ dosage and duration of use and is seen in 4.3% to 13.8% of patients 🔎#Lupus #SLE https://t.co/ocFSCmgVsN

— Laurent ARNAUD (@Lupusreference) February 18, 2021